Bioburden Method Suitability for Cleaning and Sanitation Monitoring: How Far Do We Have to Go? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bioburden Method Suitability for Cleaning and Sanitation Monitoring: How Far Do We Have to Go?
The author reviews test methods for microbiological cleaning processes and suggests ways to improve microbial bioburden method suitability studies.


Pharmaceutical Technology
Volume 34, Issue 8

References

1. R.L. Dyer et al., "Microbiological Tests for Equipment, Containers, Water and Air" in Standard Methods for the Examination of Dairy Products, R.T. Marshall, Ed. 17th ed. (American Public Health Association, Washington, USA, 17th ed., 2004), pp. 328.

2. R. Angelotti et al., Health. Lab. Sci. 1, 289–96 (1964).

3. J.M. Barnes, Proc. Soc. Appl. Bacteriol., 15, 34–40 (1952).

4. G.S. Brown et al., J. of Appl. Microbiol. 103 (4), 1074–1080 (2007).

5. M.S. Favero et al., J. Appl. Bacteriol., 31 (3), 336–43 (1968).

6. L.B. Rose et al., Emerg. Infect. Diseas., 10 (6),1023–1029 (2004).

7. A. Niskanen and M.S. Pohja, J. of Appl. Bacteriol. 42, 53–63 (1977).

8. V. Marshall, S. Poulson-Cook, and J. Moldenhauer, PDA J. Pharm. Sci Technol. 52 (4), 165–169 (1998).

9. S.A. Salo et al., J. of AOAC Intl. 83, 1357–1365 (2000).

10. D. Kang et al., J. of AOAC Intl. 90 (3), 810–816 (2007).

11. J.F. Frank, "Microbial attachment to food and food contact surfaces" in "Advances in Food and Nutrition Research," Taylor, S.L., Ed. (CA. Academic Press, San Diego, Vol. 43, 2001) pp. 320–370.

12. G. Moore and C. Griffith, Dairy, Food, and Environmental Sanitation 22 (6), 410–421 (2002a).

13. G. Moore and C. Griffith, Food Microbiol. 19, 65–73 (2002b).

14. J.W. Costerton et al., Annu. Rev. Microbiol. 49, 711–745 (1995).

15. H.D. Kusumaningrum et al., Intl. J. of Food Microbiol. 85 (3), 227–236 (2003).

16. PDA Technical Report No. 29, "Points to Consider for Cleaning Validation," PDA J. Pharm.Sci. and Tech., 52 (6), 1–23 (1998).

17. FDA, Guide to Inspections of Validation of Cleaning Processes, (Rockville, MD, July 1993).

18. P. Tandon, S. Chhibber, and R.H. Reed, J. of Gen. and Mol. Microbiol., 88 (1), 35–48 (2005).

19. A.P. Williams et al., J. of Appl. Microbiol. 98 (5), 1075–1083 (2005).

20. A.A. Mafu et al., J. of Food Protection, 53 (9), 742–746 (1990).

21. L. B. Rose et al., Emerg. Infect. Diseas., 10 (6), 1023–1029 (2004).

22. D.R. Absolom et al., Appl. and Env. Microbiol., 46 (1), 90–97 (1983).

23. L.O. Egwari, and M.A. Taiwo, West Indian Med. J. 53 (3), 164–169 (2004).

24. H.H.M. Rijnaarts et al., Environ. Sci. Technol. 30 (10), 2877–2883 (1996).

25. W. Lynch, Handbook of Silicone Rubber Fabrication, (Van Nostrand Reinhold, New York, 1978).

26. X. Xie et al., Appl. Microbiol. and Biotech. 73 (3), (2006).

27. G.M. Chudzik, J. Validation Technol. 5 (1), 77–81 (1998).

28. J. Kahovec, R.B. Fox, and K. Hatada, Pure and Applied Chem. 74 (10), 1921–1956 (2002).

29. A.N. Neely and M.P. Maley, J. of Clinic Microbiol., 38 (2), 724–726 (2000).

30. A.N. Neely and M.P. Maley, Am. J. of Infect. Cont. 29 (2), 131–132 (2001).

31. Y. Endo, T. Tani, and M. Kodama, Appl. Environ. Microbiol. 53 (9), 2050–2055 (1987).

32. S. Fidai, S.W. Farer, and R.E. Hancock, Methods Mol. Biol. 78, 187–204 (1997).

33. S.J. Kim, Marine Ecology – Progress Series 26, 203–206 (1985).

34. J.C. Tiller et al., Proc. Natl. Acad. Sci. USA 98 (11), 5981–5985 (2001).

35. G. Reiser, Using Technology to Break the Contamination Chain, Business Briefing: Hospital Engineering and Facilities Management, Issue No. 2 (2005).

36. A. Winn, Medical Plastics and Biomaterials 3 (2), 16–19 (1996).

37. E. Robine, D. Derangere, and D. Robin, Inter. J. of Food Microbiol. 55 (1–3), 229–234 (2000).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here